Screener
BridgeBio Pharma BBIO Net product revenue — Cost of Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total revenues, net | 194,515 | 116,633 |
| Operating costs and expenses: | ||
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
| Total cost of revenues | 9,939 | 2,639 |
| Research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's net product revenue — cost of revenue?
- BridgeBio Pharma (BBIO) reported net product revenue — cost of revenue of $7.73M in Q1 2026.
- How has BridgeBio Pharma's net product revenue — cost of revenue changed year-over-year?
- BridgeBio Pharma's net product revenue — cost of revenue increased by 280.1% year-over-year, from $2.03M to $7.73M.
- What does net product revenue — cost of revenue mean?
- This metric captures the direct costs associated with producing and delivering the pharmaceutical products sold within a specific business segment. It includes expenses such as manufacturing, packaging, shipping, and royalty payments related to the commercialized therapies. Monitoring this cost is essential for evaluating the gross margin profile of the company's product portfolio.
Ask your AI about BridgeBio Pharma's net product revenue — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude